



A939572

**Catalog No: tcsc0305** 

Available Sizes
Size: 2mg
Size: 5mg
Size: 10mg
Size: 50mg
Specifications
CAS No: 1032229-33-6
<b>Formula:</b> $C_{20}^{H}{}_{22}^{CIN}{}_{3}^{O}{}_{3}$
Pathway: Metabolic Enzyme/Protease
Target: Stearoyl-CoA Desaturase (SCD)
Purity / Grade: >98%
<b>Solubility:</b> DMSO : ≥ 56 mg/mL (144.38 mM)
Alternative Names: stearoyl-CoA desaturase (SCD) inhibitor;SCD-inhibitor
Observed Molecular Weight: 387.86





## **Product Description**

A939572 is a potent, and orally bioavailable **SCD1** inhibitor with  $IC_{50}$  values of mSCD1 and **hSCD1**, respectively.

IC50 & Target: IC50: [1]

In Vitro: A939572 exhibits robust in vivo activity with dose-dependent desaturation index lowering effects<sup>[1]</sup>.

A939572 is a small molecule that specifically inhibits SCD1 enzymatic activity. A939572 demonstrates a significant dose-dependent decrease in proliferation in Caki1, A498, Caki2, and ACHN at day 5 ( $IC_{50}$ s of 65 nM, 50 nM, 65 nM, and 6 nM, respectively). In A939572 (SCDi) treated Caki1 and A498 cells, all five ER stress related genes are expressed at significantly increased levels compared to DMSO+BSA control, and this elevated expression can be blocked with the addition of OA-BSA<sup>[2]</sup>.

In Vivo: Athymic nude (nu/nu) mice bearing A498 ccRCC xenografts are treated with A939572 (30mg/kg, p.o.) and Tem individually or in combination over the course of four weeks, and tumor volume (mm<sup>3</sup>) is recorded. A939572 and Tem monotherapy generate similar growth responses with approximately 20-30% reductions in tumor volume (vs. placebo control) being observed upon study completion, with values reaching statistical significance only within the last week of treatment. The combination group yields over a 60% decrease in tumor volume (vs. placebo control) by study completion with significant reductions recorded after approximately 1 week of treatment<sup>[2]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!